EVFM (Evofem Biosciences) Cyclically Adjusted PB Ratio: (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Evofem Biosciences Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Evofem Biosciences  (OTCPK:EVFM) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Evofem Biosciences Cyclically Adjusted PB Ratio Related Terms


Evofem Biosciences Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Evofem Biosciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evofem Biosciences Cyclically Adjusted PB Ratio Chart

Evofem Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Evofem Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

EVFM vs LYRA, CLSDQ, ATXI: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Evofem Biosciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evofem Biosciences Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evofem Biosciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Evofem Biosciences's Cyclically Adjusted PB Ratio falls into.



Evofem Biosciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Evofem Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Evofem Biosciences's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.586/330.2130*330.2130
=-0.586

Current CPI (Mar. 2026) = 330.2130.

Evofem Biosciences Quarterly Data

Book Value per Share CPI Adj_Book
201606 16,039.000 241.018 21,974.650
201609 13,774.000 241.428 18,839.380
201612 11,915.000 241.432 16,296.464
201703 9,035.000 243.801 12,237.335
201706 6,513.000 244.955 8,779.887
201709 4,850.000 246.819 6,488.694
201712 -289,546.000 246.524 -387,839.940
201803 -2,032.444 249.554 -2,689.356
201806 404.462 251.989 530.018
201809 -718.929 252.439 -940.424
201812 -1,668.286 251.233 -2,192.744
201903 -1,923.400 254.202 -2,498.531
201906 1,431.680 256.143 1,845.685
201909 963.000 256.759 1,238.496
201912 601.385 256.974 772.783
202003 39.269 258.115 50.238
202006 1,593.930 257.797 2,041.670
202009 935.116 260.280 1,186.366
202012 31.326 260.474 39.713
202103 -257.321 264.877 -320.793
202106 108.000 271.696 131.261
202109 -708.759 274.310 -853.201
202112 -1,199.023 278.802 -1,420.122
202203 -1,293.939 287.504 -1,486.155
202206 -341.764 296.311 -380.866
202209 -95.642 296.808 -106.406
202212 -72.893 296.797 -81.100
202303 -32.639 301.836 -35.708
202306 -22.054 305.109 -23.869
202309 -9.922 307.789 -10.645
202312 -3.324 306.746 -3.578
202403 -1.451 312.332 -1.534
202406 -0.837 314.175 -0.880
202409 -0.707 315.301 -0.740
202412 -0.629 315.605 -0.658
202503 -0.614 319.799 -0.634
202506 -0.587 322.561 -0.601
202509 -0.606 324.800 -0.616
202512 -0.587 324.054 -0.598
202603 -0.586 330.213 -0.586

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Evofem Biosciences Business Description

Address 7770 Regents Road, Suite 113-618, San Diego, CA, USA, 92122
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.